Centaurus Financial Inc. Invests $1.87 Million in Halozyme Therapeutics, Inc. $HALO

Centaurus Financial Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 23,928 shares of the biopharmaceutical company’s stock, valued at approximately $1,873,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. Bank of America Corp DE purchased a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $214,504,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $196,540,000. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth $128,201,000. Jupiter Topco LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth $105,570,000. Finally, Caisse de depot et placement du Quebec purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at $83,940,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on HALO. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. UBS Group reaffirmed a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. TD Cowen upped their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Citizens Jmp raised their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $106.92 on Friday. The firm has a market cap of $12.14 billion, a price-to-earnings ratio of 31.92, a P/E/G ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.66. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The business has a fifty day simple moving average of $86.27 and a 200 day simple moving average of $74.57.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the company posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.